Increasing demand for personalised treatments, an ageing population, the rise of new manufacturing technologies and ‘digital’ medicines represent the primary growth opportunities for UK pharmaceutical businesses, according to a new report
The UK pharmaceutical sector must grasp the opportunities developments in technology and medicine offer in order to combat the challenges of an ageing population – image courtesy of Depositphotos. The report, published today (2 July) by Santander and EEF, highlights five key areas for thr UK pharmaceutical sector: Personalised medicine The…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
